Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHENObarbital for the MANagement of Severe Acute ALcohol Withdrawal Syndrome (PHENOMANAL): a Prospective Randomized Feasibility Study.

NCT03586089 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT03586089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03586089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHENObarbital for the MANagement of Severe Acute ALcohol Withdrawal Syndrome (PHENOMANAL): a Prospective Randomized Feasibility Study.
Lead sponsor
Unity Health Toronto
Phase
Not applicable
Overall status
Terminated
Start date
June 11, 2021
Completion date
July 17, 2023
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol withdrawal, alcohol withdrawal delirium, alcohol withdrawal seizures